Azienda Sanitaria Territoriale Di Pesaro E Urbino

Research site

Italy Viale Vittorio Veneto 2, 61032 Fano, Italy

6 trials recruiting
Non-small cell lung cancer · Non-small cell lung cancer stage IV · Colitis ulcerative
Adult patients

About Specializations

Azienda Sanitaria Territoriale Di Pesaro E Urbino in Fano, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer stage IV, Colitis ulcerative, Oesophageal adenocarcinoma, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Viale Vittorio Veneto 261032 FanoItaly

Open in maps ↗

Recruiting now: 6 trials
Conditions studied: 10

More sites in Fano Italy

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

9 clinical trials

Colitis ulcerative

Recruiting

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Mirikizumab
Sponsor:Eli Lilly & Co.

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo

Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Fondazione GONO G.I.

Contact Research Centre

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Pfizer Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

Registered drugNo placebo

A Study of Telisotuzumab Adizutecan Compared to Standard Treatment in Adults with Advanced Non-Small Cell Lung Cancer After Previous Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with pembrolizumab versus platinum chemotherapy with pembrolizumab for patients with untreated HER2-positive non-small cell lung cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Non-small cell lung cancer stage IV

Recruiting

Study on the Effectiveness and Safety of Carboplatin, Pemetrexed, and Lorlatinib for ALK Positive Non-Small Cell Lung Cancer with Extracranial Progression

Registered drugNo placebo

Study on the Effectiveness and Safety of Carboplatin, Pemetrexed, and Lorlatinib for ALK Positive Non-Small Cell Lung Cancer with Extracranial Progression

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Centro Di Riferimento Oncologico Di Aviano

Contact Research Centre

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Not yet recruiting

Registered drugNo placebo

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:ASP3082
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Breast cancer

Not recruiting

Study on Chemotherapy and Aromatase Inhibitors (Exemestane, Letrozole, Anastrozole) for Post-Menopausal Patients with Early Breast Cancer

Registered drugNo placebo

Study on Chemotherapy and Aromatase Inhibitors (Exemestane, Letrozole, Anastrozole) for Post-Menopausal Patients with Early Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:IRCCS Ospedale Policlinico San Martino

Contact Research Centre

Triple negative breast cancer

Not recruiting

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Avelumab
Sponsor:Universita Degli Studi Di Padova

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites